

Analyst

Accepted Manuscript

This article can be cited before page numbers have been issued, to do this please use: R. Di Lorenzo, I. Neri, R. Raimondo, D. D. Matteo, C. Irace, M. G. Ferraro, M. Verrillo, T. Ponticorvo, T. Di Serio, S. Laneri and L. Grumetto, *Analyst*, 2026, DOI: 10.1039/D6AN00048G.



This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.

Keywords: *citrus lemon peels; green extraction; circular economy; bioactive compounds.*

Abstract

The upcycling of agro-industrial by-products represents a sustainable strategy to reduce waste, generating high-value bioactive compounds. In this study, exhausted *Citrus limon* peels—residues generated as a by-product of *Limoncello* production, a typical liquor of Southern Italy—were investigated as a potential source of bioactive compounds using supercritical CO₂ extraction. The resulting extracts were chemically characterized by gas chromatography coupled with mass spectrometry, revealed complex phytochemical profiles mainly composed of monoterpenes and oxygenated monoterpenes. Two representative extracts (EO-A and EO-B) were selected based on extraction yield, chemical profile, and safety considerations. The evaluation on human keratinocytes (HaCaT cell line) demonstrated high biocompatibility, with cell viability exceeding 90% at all tested concentrations. Antioxidant properties were assessed through ABTS and DPPH radical scavenging assays, showing significant activity, particularly for EO-B. Both extracts also exhibited antimicrobial activity against selected Gram-positive and Gram-negative bacterial strains, including *Salmonella typhi* and *Escherichia coli*. The essential oils exhibited inhibitory effects on collagenase and elastase, melanogenesis suppression, and activity against *Cutibacterium acnes*, highlighting their potential for anti-aging, skin-brightening, and antimicrobial applications. Preliminary clinical evaluations indicated improvements in skin hydration, softness, and elasticity. Overall, these findings support the use of supercritical CO₂ extraction as green, sustainable, and highly efficient technology, coupled with a well-established and widely recognized

48 analytical technique, converting a waste as lemon peel, into new assets, as
49 multifunctional, eco-sustainable cosmetic ingredients.

50 Introduction

51 The “upcycling” paradigm gains increasing attention, to reuse a waste. Unlike
52 traditional recycling, which generally disposes of the original material after use,
53 upcycling focuses on preserving – and in many cases enhancing – the functional
54 qualities of organic by-products through their reuse in high-value applications.
55 Therefore, the concept of upcycling is closely aligned with the principles of
56 sustainability, contributing to waste reduction, innovation in product design and
57 better environmental management. Beyond the environmental advantages, this
58 approach is now being successfully to industrial sectors, particularly, where
59 demand for natural and sustainable ingredients keeps growing.

60 The food processing industry contributes significantly to the production of
61 organic waste usually discharged in landfills or incinerated, leading to
62 considerable economic and environmental impacts. By-products from the agro-
63 food industry, including peels, seeds, stems, wastewater and pulp, can account
64 for over 40% of the total biomass of some plant foods, such as citrus fruits,
65 papaya, pineapple and asparagus ¹.

66 Among the most promising raw materials we find citrus by-products -
67 particularly lemon peels - which are abundant, low-cost, and rich in valuable
68 phytochemicals ².

69 Citrus plants (*genus Citrus*, family Rutaceae), also known as agrumes, are one of
70 the world’s major fruit crops with global availability and popularity contributing
71 to human diet. They are rich in vitamin C, vitamins B (thiamine, pyridoxine,
72 niacin, riboflavin, pantothenic acid, and folate) and phytochemicals, such as
73 carotenoids, flavonoids, and limonoids³. Citrus processing generates large

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

74 quantities of agricultural by-products, which can be valuable sources of bioactive
75 compounds and essential oils⁴. Among these, lemon (*Citrus limon*) residues are
76 particularly attractive due to their abundance and phytochemicals richness.

77 Essential oils (EOs) are composed of many valuable mixtures of hydrocarbons,
78 oxygenated compounds and non-volatile residues, including terpenes,
79 sesquiterpenes, aldehydes, alcohols, esters and sterols. EOs from *Citrus limon*
80 are well known due to their strong antimicrobial, antioxidant and anti-
81 inflammatory properties and have several potential applications, including use as
82 food additives, preservatives against spoilage, pharmaceuticals and
83 cosmeceuticals⁵.

84 In Southern Italy, the Campania region stands out for its extensive citrus
85 cultivation. A significant portion of this cultivation is dedicated to “*Limoncello*”
86 production, a traditional liqueur made by steeping lemon peels in ethanol.
87 Producing just one litre of “*Limoncello*” requires approximately fifteen lemons,
88 resulting in a substantial amount of exhausted lemon peel waste.

89 In this scenario our research aimed at developing an important resource for the
90 circular economy, creating a virtuous cycle of by-product reuse, proposing the
91 valorisation of wastes derived from “*Limoncello*” production, using supercritical
92 fluid extraction (SFE). EOs obtained from the extraction were characterized for
93 chemical composition and evaluated for their activity *in vitro* and *in vivo*.

94 In recent years, green extraction techniques emerged as sustainable alternatives
95 to conventional methods for isolating phytochemicals (PCs), by reducing or
96 eliminating the use of organic solvents and operating under energy-saving
97 conditions, allowing the selective isolation of thermolabile bioactive molecules.

98 Accordingly, the present study aimed at valorising exhausted lemon peels as a
99 sustainable source of functional EOs through green extraction technologies for
100 potential cosmetic applications. This work can represent a novel contribution by

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

01 demonstrating the valorisation of exhausted lemon peel waste a matrix that has
02 been largely overlooked compared to fresh citrus by-products. In particular, the
03 application of supercritical fluid extraction, the integration of chemical
04 characterization with both *in vitro* and *in vivo* bioactivity assessment reinforces
05 their relevance within a circular economy framework.

06 **Materials and methods**

07 *Citrus limon* L. (var. “Sfusato Amalfitano”) is one of the six Italian lemon
08 cultivars recognized with Protected Geographical Indication (IGP), distinguished
09 by its unique local microclimate and organic farming practices. The spent peels
10 remaining after the alcoholic extraction used to produce the liqueur, were
11 supplied by “*Distillerie Nastro D’Oro*,” a local lemon-liqueur manufacturer in
12 Naples, Italy and stored at $-20\text{ }^{\circ}\text{C}$, until the extraction procedures were carried
13 out. Frozen samples (18 kg of fresh lemon peel matrix) underwent freeze-drying
14 using a Buchi Lyovapor L-300 system and were subsequently grounded with a
15 food grinder. EOs from *Citrus limon* peels were extracted through supercritical
16 CO_2 extraction (SC- CO_2) using a pilot-scale supercritical CO_2 extractor (SCFN-
17 L7[®], SepareCo, Turin, Italy) equipped with a seven liters extraction vessel. Food-
18 grade CO_2 was supplied by Nippon Gases (Milan, Italy). The extractor was
19 equipped with PLC (Programmable Logic Controller) and SCADA (Supervisory
20 Control and Data Acquisition) systems to ensure accurate process control and
21 reproducibility. The extraction variants were obtained by carefully modulating
22 the operational parameters, such as pressure, temperature, and CO_2 flow, with
23 the aim of optimizing both the yield and the quality of the extracts, investigating
24 the impact of individual operating parameters on yield, performing the extraction
25 at pressures of 200–300 bar, temperatures of 50–60 $^{\circ}\text{C}$, and CO_2 flow rates of
26 10–20 $\text{kg}\cdot\text{h}^{-1}$. The operating conditions for each variant are reported below:

Table 1. Operational conditions for supercritical CO₂ extraction of *Citrus limon* peels.

SFE conditions			
Extract	Pressure (bar)	Temperature (°C)	Flow (Kg/h)
EO A	200	60	20
EO B	300	60	10
EO C	300	50	20
EO D	300	50	10
EO E	200	50	10
EO F	200	60	10

Each extraction trial was conducted in duplicate to ensure the reproducibility of the process and the reliability of the results. EO fractions were recovered at the end of each process, with only one EO fraction for each condition and stored in amber glass vials at 4 °C, for subsequent analyses.

The yield of extraction was calculated as follows:

$$\text{yield} = \frac{\text{matrix quantity (g)}}{\text{extract quantity (g)}} \times 100$$

where *matrix quantity* refers to grams of matrix weighted analytically and submitted to extraction; *extract quantity* is the weight of the final collected eluate.

Gas Chromatography-Mass Spectrometry analysis (GC-MS)

Agilent 6850 Series II gas chromatograph equipped with a single-quadrupole mass selective detector (Agilent 5973 Network) was employed. Ionization was

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200

carried out by electron impact (EI) at 70 eV, with the instrument scanning masses between 40 and 350 m/z. Separation was performed on a DB-5ms capillary column (5% phenyl–95% methylpolysiloxane; 30 m × 0.25 mm i.d.; 0.25 μm film thickness). Helium served as the carrier gas, flowing at 1.0 mL min⁻¹. The injector operated at 280 °C, in split mode (9:1). A 5 μL aliquot of each EO was introduced into the system using a 7683 Automatic Liquid Sampler (Agilent). The oven temperature program started at 50 °C, and increased to 300 °C, at a rate of 10 °C, min⁻¹. Identification of EOs constituents relied on matching both retention times and mass spectra with entries from the National Institute of Standards and Technology (NIST) Library, NIST 2020 MS Database. Each sample was injected in triplicate, and results are reported as the mean relative percentage composition.

Study Design

The study was structured as a multi-phase experimental protocol encompassing the supercritical CO₂ extraction of EOs from exhausted lemon peels, preclinical investigations on human skin cell models (HaCaT) and cell-free biochemical systems, and a pilot randomized short-term clinical trial. Cell biocompatibility and preliminary assessments of antioxidant and antimicrobial properties were also carried out. Specifically, cell viability was evaluated through the MTT assay on human keratinocytes (HaCaT cell line), while antioxidant potential was determined through ABTS and DPPH radical scavenging assays. Antimicrobial activity was assessed by the disk diffusion assay (DDA) and well diffusion (MIC) methods against representative Gram-positive and Gram-negative bacterial strains.

The clinical phase consisted of a randomized, monocentric, double-blind, placebo-controlled short-term study conducted on healthy human volunteers. The

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

171 primary endpoint was the assessment of cutaneous tolerability of the cosmetic
172 formulations through a 48-hour occlusive patch test, while secondary outcomes
173 included instrumental evaluations of skin hydration, softness, and elasticity using
174 standardized, non-invasive probes. Skin parameters were assessed at baseline
175 (T0) and after 1 hour (T1h) following topical application of the tested
176 formulations. This approach is consistent with established cosmetic testing
177 protocols aimed at detecting rapid, instrumentally measurable changes in skin
178 parameters (e.g., hydration and elasticity), while minimizing inter-individual
179 variability and ensuring high sensitivity in capturing early functional responses
180 of the formulations.

181 *HaCaT cell culture*

182 HaCaT cells, an immortalized human keratinocyte cell line obtained from ATCC,
183 were cultured in DMEM (Invitrogen) supplemented with 10% foetal bovine
184 serum (FBS, Cambrex), 2 mM L-glutamine, penicillin (100 U/mL, Sigma-
185 Aldrich), and streptomycin (100 µg/mL). Cells were maintained at 37°C in a
186 humidified atmosphere with 5% CO₂ and seeded at a density of 2–4 × 10⁴
187 cells/cm² and allowed to grow to approximately 80–90% confluence.

188 *Assessment of EO-A and EO-B biocompatibility*

189 The biocompatibility of two selected essential oils, EO-A and EO-B, extracts was
190 assessed through the calculation of a “cell survival index”, derived from the
191 combined evaluation of cell viability and automatic cell count⁶. Cells were seeded
192 in 96-well plates at a density of 104 cells/well and allowed to grow for 24 h.
193 Subsequently, cells were treated with EO-A and EO-B using a concentration
194 range from 0→1000 µg/mL for 48 h. DMSO was used as a vehicle to solubilize
195 the extracts. DMSO toxicity was evaluated in control cultures at a concentration

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

96 ranging from 0.025 to 0.5% v/v to exclude interference with cell viability. The
97 final DMSO concentration in all treatments did not exceed 0.5%. Cell viability
98 was evaluated by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
99 bromide (MTT) assay procedure, a colorimetric assay based on the ability of
100 active mitochondria to convert the yellow MTT solution into insoluble purple
101 formazan, evaluating cellular mitochondrial dehydrogenase activity levels. The
102 assay was performed according to the manufacturer's instructions (Sigma-
103 Aldrich, cat. no. 475989). The absorbance was measured at 550 nm by using a
104 microplate reader (Thermo Fisher). Cell number was determined using a TC20
105 automated cell counter (Bio-Rad, Milan, Italy), which provides accurate and
106 reproducible total count of cells and a live/dead ratio through trypan blue
107 exclusion assay. The assay was performed according to the manufacturer's
108 instructions (1450021 Bio-Rad).

109 110 *Antioxidant Activity Evaluation*

111 Since no single assay can accurately reflect the wide range of antioxidant
112 properties in complex systems such as EOs, their antioxidant activity was
113 appraised using two complementary methods: the DPPH and ABTS assays.

114 *DPPH Radical Scavenging Assay*

115 For the free radical scavenging activity, 30 µg of EO-A and EO-B were incubated
116 in 0.4 mL of 0.1 M Tris-HCl (pH 7.5 ± 0.1) and 0.5 mL of 0.3 mM DPPH in the
117 dark at room temperature (20 ± 2°C) for 20 min. The absorbance (A_{sample}) was
118 measured at 517 nm using a PerkinElmer Lambda 25 UV/Vis Spectrometer and
119 compared to a reference (A_{control}) consisting of 80% methanol, 0.1 M Tris-HCl,

and 0.5 mL of 0.3 mM DPPH, which served to monitor the maximum radical stability.

The scavenging percentage was calculated using the formula:

$$\% \text{ DPPH scavenging} = (1 - A_{\text{control}} / A_{\text{sample}}) \times 100$$

To ensure a precise quantitative assessment, results were expressed as IC₅₀ values (the concentration required to inhibit 50% of the DPPH radical). These values were derived from a dose-response calibration curve generated by testing each EO at multiple concentrations. Ascorbic acid was utilized as a positive control to validate the assay's sensitivity and provide a benchmark for high antioxidant potency.

ABTS Radical Cation Decolorization Assay

Parallely, the ABTS assay was performed by reacting a 0.007 M ABTS solution with 2.45 mM potassium persulfate for 16 h in the dark to produce the ABTS^{•+} radical cation. This stock was diluted with ethanol to an absorbance of 0.7±0.02 at 734 nm. For the analysis, 4 mg of each EO (EO-A and EO-B) were dissolved in 2 mL of DMSO solution (5%), and 100 µL of this solution were added to 1.9 mL of the ABTS^{•+} working solution.

After 2 min of reaction in the dark, the absorbance was measured at 734 nm using a VitroScan Multiwell Reader. The antioxidant capacity was quantified as Trolox Equivalent Antioxidant Capacity (TEAC). This value was calculated by interpolating the absorbance data into a linear calibration curve of Trolox (a water-soluble vitamin E analogue) prepared in the range of 0.1–100 mg/L (R²=0.998).

243 *Quality Control and Validation*

244 All experiments were performed in triplicate to ensure reproducibility. To
245 confirm the accuracy of the multiwell system and the stability of the radicals,
246 negative controls (solvents without EOs) and reference standards were processed
247 alongside the samples, ensuring that all data met the required validation criteria
248 for precision and linearity. Since no single assay can accurately reflect the wide
249 range of antioxidant properties in complex systems such as EOs, their antioxidant
250 activity was appraised using two complementary methods: the DPPH and ABTS
251 assays. For the free radical scavenging activity, 30 µg of each EO sample were
252 incubated in 0.4 mL of 0.1 M Tris-HCl (pH 7.5 ± 0.1) and 0.5 mL of 0.3 mM
253 DPPH in the dark at room temperature (20±2°C) for 20 min. The absorbance
254 (A_{sample}) was measured at 517 nm using a PerkinElmer Lambda 25 UV/Vis
255 Spectrometer (PerkinElmer Inc., Waltham, MA, USA) and compared to a
256 reference (A_{control}) consisting of 80% methanol, 0.1 M Tris-HCl, and 0.5 mL
257 of 0.3 mM DPPH. The scavenging percentage was calculated as % DPPH
258 scavenging $(1 - A_{\text{sample}} / A_{\text{control}}) \times 100$, and results were further expressed as
259 IC₅₀ values (the concentration required to inhibit 50% of the DPPH radical)
260 derived from a dose-response curve, using Ascorbic acid as a positive control.
261 Parallely, the ABTS assay was performed by reacting a 0.007 M ABTS solution
262 with 2.45 mM potassium persulfate for 16 h in the dark to produce the ABTS·⁺
263 radical cation. This stock was diluted with ethanol to an absorbance of 0.7±0.02
264 at 734 nm. For the analysis, 4 mg of each EO were dissolved in 2 mL of DMSO
265 solution (5%), and 100 µL of this solution were added to 1.9 mL of the ABTS·⁺
266 working solution. After 2 min of reaction in the dark, the absorbance was
267 measured at 734 nm using a VitroScan Multiwell Reader (Diatron MI PLC,
268 Budapest, Hungary). Results were expressed as Trolox Equivalent Antioxidant

Capacity (TEAC), based on a linear calibration curve of Trolox in the range of 0.1–100 mg/L ($R^2=0.998$). All experiments were performed in triplicate to ensure reproducibility, and data were validated against reference standards to confirm the accuracy of the multiwell system.

Antibacterial Activity Evaluation

The antibacterial activity of EO-A and EO-B was evaluated by disk diffusion assay (DDA) and broth microdilution method (MIC). Bacterial strains used in this work include *Staphylococcus aureus* ATCC 6538P, *Enterococcus faecalis* ATCC 29212, *Listeria monocytogenes* ATCC19115, *Salmonella typhi* ATCC14028, *Escherichia coli* ATCC 33780 and *Bacillus cereus* ICE170.

Three independent experiments were performed for each DDA and MIC value. The DDA was performed according to the National Committee for Clinical Laboratory Standards (NCCLS) standard method, using 30 μg of each tested sample. The inoculum of the colonies was suspended in sterile saline and that the inoculum was adjusted to 10^8 CFU mL^{-1} (0.5 McFarland standard), which is equivalent to 50% transmittance at 580 nm (Coleman model 6120, Maywood, IL, USA). Subsequently, 200 μL of the bulk suspensions was placed onto the surface of Mueller–Hinton agar. Disks (6.0 mm diameter) were impregnated with 25 μL of a solution 1.2 mg/mL of each sample placed on the agar Petri dish and incubated at 37 °C, for 24 h. Sterile distilled water (25 μL), and ampicillin and clavulanic acid (30 μg) were used control negative and positive reference, respectively. The total diameters were measured by considering the size of the inhibition zones. Each experiment was performed in triplicate. The second antimicrobial assay was performed by the broth microdilution method in a Mueller–Hinton broth medium by using sterile 96-well polypropylene microtiter plates. The microbial inoculum size used was $1 \times$

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

295 10^6 CFU mL⁻¹ (NCCLS, 1993). Two-fold serial dilutions of different samples
296 were carried out to obtain concentrations ranging from 10 to 1000 µg/mL. Then,
297 the bacterial cells were inoculated from an overnight culture at a final
298 concentration of about 5×10^5 CFU mL⁻¹ per well and incubated with different
299 samples overnight at 37 °C. The minimal inhibitory concentration (MIC) values-
300 that is, the lowest concentration of material that inhibited the growth of
301 microorganisms after 24 h of incubation at 37 °C, - were estimated by measuring
302 the spectrophotometric absorbance at 570 nm using VitroScan Multiwell Reader.

303 *Statistical Analysis and Data Processing*

304 To ensure the reliability and reproducibility of the results, all antimicrobial tests
305 (DDA and MIC) were performed in triplicate (n=3) across three independent
306 experimental sessions. Data are expressed as Mean ± Standard Deviation (SD).
307 Statistical significance between the antibacterial activities of EO-A, EO-B, and
308 the positive controls was evaluated using One-way Analysis of Variance
309 (ANOVA), followed by Tukey's Honest Significant Difference (HSD) post-hoc
310 test to identify specific differences between the groups. All statistical analyses
311 were performed with a significance threshold set at p<0.05 using XLSTAT
312 software (Addinsoft, Paris, France).

313 *EOs-Based Topical Formulation Preparation*

314 Oil-in-water (o/w) emulsions were prepared using the hot emulsification method.
315 According to Table 2, consisting of deionized water (71.78% w/w) and disodium
316 EDTA (0.10% w/w), was heated under magnetic stirring (200 ± 25 rpm) from 60
317 °C to 70 °C until complete dissolution.

318 In parallel, the oil phase (Phase B), composed of Glyceryl Stearate SE (6.00%
319 w/w), Cetylstearyl alcohol (3.00% w/w), Vegetable stearin (2.00% w/w),

320 Butylated hydroxytoluene (0.02% w/w), Ethylhexyl stearate (3.00% w/w),
 321 Isopropyl myristate (2.00% w/w), and Dicaprylyl ether (1.00% w/w), was heated
 322 separately to 75 °C until complete melting of the solid components.

323 The oil phase was then slowly added to the aqueous phase under high-shear
 324 mixing (6000 rpm for 5 min) to obtain a homogeneous emulsion. The system was
 325 subsequently cooled under moderate stirring to below 40 °C.

326 At this stage, Phase C—containing the preservative system (Phenoxyethanol and
 327 Ethylhexylglycerin, 1.00% w/w), Caprylic/capric triglyceride (4.00% w/w),
 328 Dimethicone (1.00% w/w), Glycerin (4.00% w/w), and the selected essential oil
 329 (1.00% w/w)—was added under low-shear mixing (2000 rpm for 2 min).

330 Finally, the emulsion was adjusted to pH 5.5 using a 30% sodium hydroxide
 331 solution (0.10% w/w), and the final product was left to stabilize for 24 h before
 332 analysis.

33
 34 **Table 2.** Composition of EOs-containing o/w emulsion

Phase	INCI name	Function	% w/w
A	Water	Solvent	71.78
A	Disodium EDTA	Chelating agent	0.10
B	Glyceryl Stearate SE	Emulsifying	6.00
B	Cetylstearyl alcohol	Viscosity controlling	3.00
B	Vegetable stearin	Emulsifying	2.00
B	Butylated hydroxytoluene	Antioxidant	0.02
B	Ethylhexyl stearate	Emollient	3.00
B	Isopropyl myristate	Emollient	2.00
B	Dicaprylyl Ether	Emollient	1.00

C	Citrus limon (Lemon) peel extract	Active ingredient	1.00
C	Caprylic/capric triglyceride	Emollient	4.00
C	Dimethicone	Emollient	1.00
C	Glycerin	Humectant	4.00
C	Phenoxyethanol (and) Ethylhexylglycerin	Preservative	1.00
C	Sodium hydroxide	pH modifier	0.10

Clinical Trial

The randomized, double-blind, placebo-controlled efficacy study was conducted in accordance with the quality management system for cosmetic clinical trials (IMQ S.p.A, Milan, Italy) and complied with the UNI EN ISO 9001 standard (European Commission, 2018). The study protocol adhered to the principles of the Declaration of Helsinki, (World Medical Association, 2013) and the COLIPA Guidelines for the Evaluation of the Efficacy of Cosmetic Products (Cosmetics Europe, 2008b). Considering the non-invasive nature of the procedures and the inclusion of healthy adult volunteers, ethical committee approval was not required⁷. All participants provided written informed consent prior to enrolment.

Forty healthy volunteers (aged 20 –70 years), regular users of cosmetic products, were enrolled and randomly assigned to one of the three treatment groups (Group 1: topical formula containing 1% w/w EO-A; Group 2: topical formula containing 1% w/w EO-B and Group 3: placebo). Following a seven-day wash-out period, participants applied approximately 2 mg of the assigned formulation evenly to

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

351 the entire facial area for 1 hour. All measurements were performed at baseline
352 (T_0) and after 1 hour (T_{1h}) by the same trained operator, following a 30-minute
353 acclimatization period under controlled environmental conditions (20 ± 2 °C; 50
354 $\pm 5\%$ relative humidity).

355 The primary endpoint was the evaluation of cutaneous tolerability, assessed
356 through a 48-hour occlusive patch test performed under medical supervision. The
357 test was conducted on intact skin of the volar forearm to evaluate the potential
358 irritant properties of the formulations, in compliance with EEC Directive 76/768.
359 The Finn Chambers® AQUA patch system (Epitest Ltd., Finland) was used
360 according to standardized procedures⁸. Reactions were scored based on the
361 morphological criteria established by the International Contact Dermatitis
362 Research Group, with an irritancy threshold set at 1.5 on a 0–3 visual scale. No
363 adverse skin reactions or signs of irritation were observed, confirming the good
364 tolerability profile of both formulations.

365 The secondary endpoint was the evaluation of short-term effects on skin
366 hydration and mechanical properties. Instrumental assessments included
367 corneometry (skin hydration), skin softness, and skin elasticity, measured using
368 widely recognized, non-invasive devices. Specifically, skin hydration was
369 assessed using the Corneometer® CM 825, skin softness with the Indentometer®
370 IDM 800, and skin elasticity with the Cutometer® MPA 580. The latter was
371 evaluated using the R2 parameter (gross elasticity), calculated as U_a/U_f , which
372 is considered a robust indicator of the skin's ability to recover its original shape
373 after deformation and reflects the condition of collagen, elastin, and extracellular
374 matrix components⁹.

375 *Statistical Analysis in clinical trial*

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

376 A total of 40 participants were enrolled in the clinical trial and randomly
377 assigned to two treatment groups, with twenty subjects per group (EO-A and EO-
378 B). This sample size was considered adequate to ensure sufficient statistical
379 power for detecting clinically relevant differences between treatments. Intra-
380 group comparisons, expressed as mean percentage changes from baseline, were
381 analysed using the paired Student's t-test. A p-value < 0.05 was considered
382 statistically significant. In addition to p-values, 95% confidence intervals (CI)
383 were calculated for all primary outcome measures to provide an estimate of the
384 precision and reliability of the observed effects. Effect sizes were also
385 determined using Cohen's d, allowing quantitative interpretation of the
386 magnitude of treatment-related changes beyond statistical significance. All
387 statistical analyses were performed using SAS® software, version 9.4 (SAS
388 Institute Inc., Cary, NC, USA).

89 90 **Results and Discussion**

391 392 *SC-CO₂ and GC-MS analysis*

393 The extraction of EOs from lemon by-products is a critical process where the
394 method chosen directly impacts the oil's chemical integrity, aroma, and
395 bioactivity. While conventional methods remain the industrial standard, there is
396 a significant shift toward "green" technologies to improve efficiency and preserve
397 quality ¹⁰.SFE is considered safe and sustainable, offering advantages such as
398 adjustable solvating power, low-temperature operation, and the complete
399 removal of solvent residues ¹¹. Besides, carbon dioxide, with a critical point of
400 31.1°C and 73.8 bar, is ideal for extracting lipophilic components like essential

oils while preserving their structural integrity. Its non-toxic, inert, and recyclable characteristics further contributes to the environmentally friendly profile of the process.

The extraction process is influenced by several characteristics of matrix such as the particle size, shape, surface area, porosity, moisture, because the diffusion of CO₂ into the matrix is related to its features and for this reason a pretreatment is usually recommended¹². Indeed, before being extracted, the lemon peels were undertaken freeze-drying and then grinded. Moreover, the different combinations of operational parameters, particularly pressure, influence the solubility of CO₂ and, consequently, the affinity between CO₂ and the bioactive compounds in the matrix. This directly impacts the compositional profile of the obtained extracts, as the extraction efficiency and selectivity of compounds depend on these conditions.

The quantitative yields of the extracts were influenced by the operational conditions:

Table 3. Quantitative yields of the supercritical CO₂ extracts from *Citrus limon* peels under different operational conditions.

Extract	Yield (g extract/g matrix)
EO-A	2.22%
EO-B	3.70%
EO-C	8.20%
EO-D	10.18%
EO-E	2.26%
EO-F	2.61%

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

422 A comparison between extracts C and D demonstrates the critical impact of flow
423 rate on performance. At a constant 300 bar and 50°C, the lower flow rate of 10
424 kg/h (EO-D) outperformed the 20 kg/h flow (Extract C), yielding 10.18% versus
425 8.20%. These findings suggest that a slower passage of the solvent allows for
426 more thorough extraction, making flow rate a key factor in yield optimization.
427 Following SFE optimization, the obtained EOs were characterized via GC–MS
428 to map their chemical profiles. Compound identification was performed by
429 matching mass spectra with the NIST 2020 MS Database. While the use of
430 authentic standards is the gold standard for absolute quantification, this study
431 opted for library-based qualitative profiling. This approach was deemed the most
432 appropriate and efficient to establish the chemical fingerprint of the extracts to
433 evaluate their suitability for cosmetic formulations. In the context of a circular
434 economy, the primary objective was to determine the functional ingredients of
435 the recycled byproduct rather than a comprehensive fine characterization¹³.

3
3
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

36
37 Table 4 and Table 5 report the chemical composition of the two selected lemon
438 EOs, *i.e.* EO-A and EO-B. The rationale for the choice of the EO- A and EO-B
439 by a chemical point of view, was based on their low levels of potentially
440 allergenic constituents — such as limonene) — and/or other potential hazardous
441 chemicals, thereby reducing sensitization risks and enhancing the overall safety
442 of the possible final formulation. In this context, a higher quantitative extraction
443 yield does not necessarily translate into a qualitative advantage.

44
45
46
47
48
49
50
51
52
53
54
55

444 Indeed, during “*Limoncello*” manufacturing, the ethanol maceration of lemon
445 peels leads to the extraction of volatile compounds such as D-limonene into the
446 liqueur, leaving the residual peel matrix considerably depleted in these
447 compounds. This depletion is advantageous for cosmetic applications. D-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

448 limonene, upon air exposure and subsequent oxidation, produces hydroperoxides
449 that are recognized as potent sensitizers ¹⁴.

450 Despite the depletion of high-volatility terpenes, both lemon EOs retained a
451 complex phytochemical composition, mainly characterized by monoterpenes and
452 oxygenated monoterpenes, with additional contributions from sesquiterpenes and
453 coumarin derivatives.

454 SFE of exhausted biomass produces non-conventional EO profiles, yielding a
455 composition markedly enriched in oxygenated monoterpenes. This composition
456 differs from typical profiles obtained by conventional methods with SFE
457 particularly effective in recovering residual, more polar and matrix-bound
458 compounds that are not easily accessible through traditional techniques.

459 Moreover, the presence of coumarin suggests that the SFE enhanced the
460 solubilization of higher molecular weight and less volatile constituents.
461 Importantly, the relatively high abundance of oxygenated compounds indicates
462 that SC-CO₂ extraction minimized thermal and oxidative transformations, which
463 are typically associated with conventional extraction methods.

464 Overall, these results highlight that, when applied to exhausted citrus matrices,
465 SFE extraction shifts the volatile profile from hydrocarbon-dominated to
466 oxygenated and semi-volatile compounds, enabling the recovery of a distinct
467 fraction with potential added value and a composition less affected by artefact
468 formation.

469 The comparison between EO-A and EO-B highlight a crucial trade-off between
470 total yield and the concentration of active bioactive markers. Indeed, while EO-
471 B resulted in a higher extraction yield (3.70%) compared to EO-A (2.22%), the
472 latter showed a significantly higher relative abundance of key coumarin
473 derivatives, such as Citropten (5,7-dimethoxycoumarin) and Scoparone (6,7-
474 dimethoxycoumarin). Furthermore, the EO-A is significantly more concentrated

in oxygenated monoterpenes particularly monoterpenoid alcohols ($\approx 30\text{--}35\%$), and phenolic compounds, while EO-B showed a higher percentage of fatty acids and their esters, for instance Linoleic acid reached 10.75%. The higher pressure used for EO-B increased the extraction of bulk lipids, which explains the higher overall yield. Coumarins have been associated with antioxidant and dermo protective action ¹⁵ while monoterpene alcohols and esters are known to contribute not only to olfactory and sensorial properties, but also to antimicrobial, antioxidant, and anti-inflammatory effects ¹⁶

Additionally, coumarin derivatives were significantly higher in EO-A ($\approx 10\text{--}11\%$) compared to EO-B ($\approx 4\%$), suggesting a selective extraction of these semi-polar bioactive compounds at lower pressure conditions.

Conversely, increasing pressure to 300 bar enhanced the extraction of less volatile, higher molecular weight compounds, including fatty acids and polycyclic hydrocarbons.

Table 4. Chemical composition of lemon EO-A. Extraction parameters: pressure 200 bar; flow 20 kg h⁻¹; temperature 60 °C. Extraction yield: 2.22%

Retention time	CAS Number	IUPAC Name	Chemical Class	Abundance %
5.999	594-09-2	Trimethylphosphane	Organophosphorus compound	2.85 ± 0.1
6.293	470-82-6	1,3,3-Trimethyl-2-oxabicyclo[2.2.2]octane	Bicyclic ether	0.39 ± 0.05
6.880	111-87-5	Octan-1-ol	Primary alcohol	0.56 ± 0.07
7.367	78-70-6	3,7-Dimethylocta-1,6-dien-3-ol	Monoterpenoid alcohol	1.93 ± 0.5

8.650	20126-76-5	4-Methyl-1-propan-2-ylcyclohex-3-en-1-ol	Monoterpenoid alcohol	2.74 ± 0.02
8.868	10482-56-1	2-[4-Methylcyclohex-3-en-1-yl]propan-2-ol	Monoterpenoid alcohol	9.43 ± 0.05
9.414	106-25-2	(2Z)-3,7-Dimethylocta-2,6-dien-1-ol	Monoterpenoid alcohol	8.97 ± 0.07
9.590	106-26-3	(2Z)-3,7-Dimethylocta-2,6-dienal	Monoterpenoid aldehyde	4.21 ± 0.03
9.791	106-24-1	(2E)-3,7-Dimethylocta-2,6-dien-1-ol	Monoterpenoid alcohol	9.96 ± 0.03
10.026	5392-40-5	(2E)-3,7-Dimethylocta-2,6-dienal	Monoterpenoid alcohol	6.22 ± 0.05
11.007	3564-98-5	8-Hydroxymenthol	Monoterpenoid aldehyde	1.46 ± 0.02
11.309	141-12-8	2,6-Octadien-1-ol, 3,7-dimethyl-, acetate (Z)	Monoterpenoid diol	1.75 ± 0.1
11.561	16409-44-2	3,7-Dimethylocta-2,6-dienyl acetate	Monoterpenoid ester	0.63 ± 0.05
11.905	121-33-5	4-Hydroxy-3-methoxybenzaldehyde	Monoterpenoid ester	0.78 ± 0.09
14.338	617-05-0	Ethyl 4-hydroxy-3-methoxybenzoate	Phenolic aldehyde	0.52 ± 0.03
15.260	134-96-3	4-Hydroxy-3,5-dimethoxybenzaldehyde	Aromatic ester	0.55 ± 0.08
16.812	3622-84-2	N-butylbenzenesulfonamide	Phenolic aldehyde	6.06 ± 0.02
18.532	57-10-3	Hexadecanoic acid	Sulfonamide	0.92 ± 0.02
18.851	120-08-1	6,7-Dimethoxychromen-2-one	Coumarin derivative	1.26 ± 0.06
19.002	487-06-9	5,7-Dimethoxychromen-2-one	Coumarin derivative	9.56 ± 0.01
20.352	112-80-1	(Z)-octadec-9-enoic acid	Fatty acid	3.14 ± 0.01

20.529	57-11-4	Octadecanoic acid	Fatty acid	0.49 ± 0.05
23.364	1000130-81-0	11,13-Dimethyl-12-tetradecen-1-ol acetate	Fatty acid	0.91 ± 0.01
25.679	24724-52-5	4-(2,3-Dihydroxy-3-methylbutoxy)furo[3,2-g]chromen-7-one	Long-chain aliphatic ester	1.72 ± 0.03
26.694	55806-41-2	9-(2-Hydroxy-3-methyl-3-butenyloxy)-4-methoxyfuro[3,2-g]chromen-7-one	Furanocoumarin derivative	0.75 ± 0.05

Table 5. Chemical composition of EO- B. Extraction parameters: pressure 300 bar; flow 10 kg h⁻¹; temperature 60°C. Extraction yield: 3.70%

Retention time	CAS Number	IUPAC Name	Chemical Class	Abundance %
5.773	1604-28-0	(3E)-6-Methylhepta-3,5-dien-2-one	α,β-Unsaturated ketone	0.71 ± 0.03
5.807	86951-58-8	Cyclopentanol, 1-(methylenecyclopropyl)-	Cyclopentanol derivative	1.37 ± 0.04
7.442	78-70-6	3,7-Dimethylocta-1,6-dien-3-ol	Monoterpenoid alcohol	2.84 ± 0.03
8.709	562-74-3	4-Methyl-1-propan-2-ylcyclohex-3-en-1-ol	Monoterpenoid alcohol	3.04 ± 0.02
8.936	10482-56-1	2-[4-Methylcyclohex-3-en-1-yl]propan-2-ol	Monoterpenoid alcohol	14.02 ± 0.04

9.456	106-25-2	(2Z)-3,7-Dimethylocta-2,6-dien-1-ol	Monoterpenoid alcohol	9.48 ± 0.04
9.624	106-26-3	(2Z)-3,7-Dimethylocta-2,6-dienal	Monoterpenoid aldehyde	1.40 ± 0.01
9.833	106-24-1	(2E)-3,7-Dimethylocta-2,6-dien-1-ol	Monoterpenoid alcohol	10.14 ± 0.01
10.051	5392-40-5	(2E)-3,7-Dimethylocta-2,6-dienal	Monoterpenoid aldehyde	1.95 ± 0.3
11.343	1000360-39-7	(2E)-3,7-Dimethylocta-2,6-dienyl-2-methylbutanoate	Monoterpenoid ester	0.52 ± 0.02
16.880	3622-84-2	N-butylbenzenesulfonamide	Sulfonamide	3.64 ± 0.1
18.633	57-10-3	Hexadecanoic acid	Fatty acid	1.94 ± 0.05
18.893	120-08-1	6,7-dimethoxychromen-2-one	Coumarin derivative	0.76 ± 0.02
19.036	487-06-9	5,7-Dimethoxychromen-2-one	Coumarin derivative	3.35 ± 0.02
20.512	60-33-3	(9Z,12Z)-Octadeca-9,12-dienoic acid	Fatty acid (polyunsaturated)	10.75 ± 0.01
23.423	54766-91-5	Bicyclo[10.1.0]tridec-1-ene	Polycyclic hydrocarbon	3.95 ± 0.05
23.523	1000336-54-1	Butyl 9,12-octadecadienoate	Fatty acid ester	0.55 ± 0.03
25.260	16106-03-9	Methyl (7E,10E)-hexadeca-7,10-dienoate	Fatty acid ester	1.16 ± 0.05
38.422	1000336-77-8	n-Propyl 9,12-octadecadienoate	Fatty acid ester	2.97 ± 0.02

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010

The comparative analysis of the terpenic profiles reveals a significant divergence between the data reported in literature and our experimental results. According to a recent review¹⁰ conventional and green extraction techniques typically preserve a high hydrocarbon fraction, with D-limonene dominating the bioactive profile at concentrations ranging from 46% to 76%, followed by significant percentages of gamma-terpinene and beta-pinene. In our study, these specific monoterpenes are either absent or present only in trace amounts. This discrepancy is primarily due to the unique nature of our starting matrix. Unlike the fresh peels used in conventional studies, our raw material consists of lemon peels that have already undergone an exhaustive ethanol infusion for liquor production. Despite the lower limonene concentration, the potential for these extracts remains significant.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

11
12

 *Biological Cell toxicity investigation*

513
514
515
516
517
518


In addition to qualitative–quantitative chemical characterization, the selection of EO-A and EO-B was further supported by a biocompatibility-driven criterion. Specifically, both extracts were evaluated on human keratinocytes (HaCaT cell line), showing no cytotoxic effects across the tested concentration with cell viability consistently exceeding 80%.

519
520
521
522

This biological screening allowed the exclusion of potentially irritating or cytotoxic extracts and ensured the selection of samples with a favourable safety profile for topical application. Therefore, the final choice of EO-A and EO-B was based not only on extraction yield and chemical composition, but also on their

23 demonstrated in vitro biocompatibility, strengthening their suitability as cosmetic
24 ingredients.

25 To evaluate the biocompatibility of two selected EOs, namely EO-A and EO-B,
26 obtained from ethanol-exhausted *Citrus limon* (L.) peels, targeted in vitro
27 bioscreen assays were performed on immortalized human keratinocytes
28 (HaCaT). The extracts were tested at concentrations ranging from 0 to 1000
29 $\mu\text{g}/\text{mL}$ for 48 h. The resulting data, reported in Figure 1 as concentration–effect
30 curves of the “cell survival index”, showed no significant changes following in
31 vitro treatment compared with untreated cells. No biological effects or
32 interference with cell viability or proliferation were observed under the tested
33 conditions. Overall, these findings suggest a favourable safety profile for both
34 EO-A and EO-B, supporting their biocompatibility in a skin cell model. Extracts
35 were considered biocompatible if a cell survival index of at least 80% relative to
36 untreated control cells was observed, including at the highest tested concentration
37 after 48 h of exposure. This threshold was adopted as an additional selection
38 criterion for EO-A and EO-B.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

541 **Figure 1.** Preclinical biocompatibility assessment of EO-A and EO-B, essential
542 oils derived from ethanol-exhausted *Citrus limon* (L.) peels, in HaCaT cells.
543 Concentration-response curves by the “Cell survival index” for HaCaT cells after
544 48 h of treatment with EO-A and EO-B over a concentration range of 0–1000
545 $\mu\text{g/mL}$. Results are expressed as a percentage of untreated control cells and are
546 reported as the mean \pm SEM of three independent experiments ($n = 15$). Statistical
547 analysis was performed by one-way ANOVA followed by Tukey’s multiple
548 comparisons test. No statistically significant differences were observed
549 compared with untreated control cells.

551 *Antioxidant activity*

552 As previously reported, based on comprehensive MTT cytotoxicity screening
553 conducted on two selected EOs derived from ethanol-exhausted *Citrus limon* (L.)
554 peels, and considering their distinctive chemical profiles and extraction yields,
555 EO-A and EO-B were selected as representative samples for further biological
556 characterisation and subsequent evaluation in the clinical trial.

557 Antioxidant substances provide significant protection against various diseases
558 related to oxidative stress, typically induced by free radicals such as reactive
559 nitrogen species (RNS) and reactive oxygen species (ROS)¹⁷. Consequently, the
560 radical scavenging activities of phenolic components in natural molecules,
561 characterized by their electron donor/acceptor behaviour, have been extensively
562 discussed. In the ABTS assay, the antioxidant capacity was quantified as Trolox
563 Equivalent Antioxidant Capacity (TEAC), derived from a linear calibration curve

(R²=0.998). EO-A exhibited a TEAC value of 135.6±0.01 mmol Trolox equivalents per gram (mmol TE/g), whereas EO-B reached a significantly higher value of 167.3±0.09 mmol TE/g; these values were validated using Trolox as a positive reference standard. Regarding the DPPH test, the free radical scavenging activity was evaluated by determining both the percentage of inhibition and the IC₅₀ values (the concentration required to inhibit 50% of the DPPH radical). At the tested concentration, EO-A achieved an inhibition of 59.0%±0.05, while EO-B showed a stronger effect with 69.0%±0.08 inhibition. The corresponding IC₅₀ values further confirmed the superior potency of EO-B, showing a higher efficiency in neutralizing the DPPH radical compared to EO-A. Ascorbic acid was employed as a positive control, providing a benchmark for the EOs' performance. These results, summarized in Figure 2 a-b, and reported in Table 6 demonstrate that both samples possess a significant radical scavenging capacity,

Sample	ABTS Assay (mmol TE/g)	DPPH Inhibition (%)	DPPH IC ₅₀ (µg/mL)
EO A	135.6 ± 0.01	59.0 ± 0.05*	45.2 ± 0.15*
EO B	167.3 ± 0.09*	69.0 ± 0.08	31.8 ± 0.11
Reference Standard	Trolox	Ascorbic Acid	5.4 ± 0.03*

Table 6. Antioxidant capacity and radical scavenging activity of Essential Oils (EO A and EO B). Results are expressed as Mean±Standard Deviation (SD). The antioxidant capacity in the ABTS assay was quantified as Trolox Equivalent Antioxidant Capacity (TEAC). The values represent the concentration required to inhibit 50% of the DPPH radical; lower values indicate higher antioxidant potency. Statistical significance was evaluated using One-way Analysis of Variance (ANOVA), followed by Tukey's post-hoc test for multiple comparisons. Linear regression analysis was employed to determine the Trolox Equivalent Antioxidant Capacity (TEAC) and to calculate the values for the DPPH radical scavenging assay.

although EO-B consistently displayed a higher antioxidant performance across both complementary assay systems. In the DPPH test, EO-A achieved an inhibition of $59.0 \% \pm 0.05$, while EO-B showed a stronger effect with $69.0 \% \pm 0.08$ inhibition. These results demonstrate that both samples possess a significant radical scavenging capacity, although EO B consistently displayed a higher performance in both assay systems (Figure 2 a-b).



Figure 2. Antioxidant activity of EO-A and B, a) as measured by ABTS and b) DPPH assay. Vertical bars represent the standard deviation.

According to the literature, the antioxidant activity of *Citrus limon* (L.) EOs is generally attributed to its major constituents, primarily monoterpenes such as limonene, β -pinene, and γ -terpinene

According to the ability of β -pinene and limonene to scavenge hydroxyl radicals contributes to the reduction of oxidative reaction rates¹⁸. D-limonene has indeed been reported to exert measurable antioxidant effects, although oxygenated monoterpenes typically provide stronger contributions. In particular, the relatively high levels of (*Z*)-citral, α -terpinene, and α -terpineol have been associated with marked scavenging effects in DPPH assays, while γ -terpinene and (*Z*)-citral appear to be more effective in ABTS radical neutralization¹⁹.

Notably, coumarin also known as benzopyrones, are plant-derived products with several pharmacological properties, including antioxidant and anti-inflammatory activities, by which Scoparone is recognized for its potent radical scavenging

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

610 properties. Its detection provides a mechanistic basis for the enhanced antioxidant
611 activity of EO-B, as evidenced by the higher responses obtained in both ABTS
612 and DPPH assay system ²⁰.

613 *Antimicrobial properties*

614 The antimicrobial activity of both EO samples, evaluated through the Disk
615 Diffusion (DDA) and Minimum Inhibitory Concentration (MIC) assays, is
616 quantitatively summarized in Table 7. The samples were tested against a
617 representative panel of Gram-positive bacteria (*Staphylococcus aureus*,
618 *Enterococcus faecalis*, *Bacillus cereus*, *Listeria monocytogenes*) and Gram-
619 negative strains (*Salmonella typhi*, *Escherichia coli*). The most pronounced
620 inhibition was observed against *S. typhi*, which exhibited mean inhibition
621 diameters of 10.8 mm for EO-A and 8.7 mm for EO-B. Significant activity was
622 also recorded against *E. coli*, particularly for EO-B (10.2 mm), and against *B.*
623 *cereus*, where both samples produced inhibition zones exceeding 8 mm.
624 Conversely, lower susceptibility was observed for *E. faecalis* and *L.*
625 *monocytogenes*, with inhibition zones not exceeding the disk diameter (6 mm).
626 The MIC values strongly correlated with the DDA trends; *S. typhi* showed the
627 highest susceptibility with MICs of 125 µg/mL for EO-A and 100 µg/mL for EO-
628 B, supporting the previously noted inhibition zones. Similarly, *E. coli*
629 demonstrated moderate sensitivity, especially to EO-B (MIC = 125 µg/mL). Both
630 EOs showed comparable inhibitory effects against *B. cereus* (MIC = 250 µg/mL),
631 while relatively high MIC values (>500 µg/mL) were recorded against *E. faecalis*
632 and *L. monocytogenes*, indicating reduced efficacy. These quantitative data
633 confirm the broader antimicrobial potential of EO B, particularly against Gram-
634 negative strains. To ensure assay validity, the positive control (Ampicillin +

Clavulanic acid) yielded substantial inhibition zones (30–40 mm) and full growth inhibition at expected concentrations, while the negative control (sterile water) showed no activity, confirming that the observed antimicrobial effects are strictly attributable to the EO samples themselves.

Table 7. Antimicrobial activity of EO-A and EO-B. Minimum Inhibitory Concentration (MIC) values of EO-A and EO-B against selected bacterial strains. MIC is expressed as the lowest concentration (in micrograms per milliliter, $\mu\text{g}/\text{mL}$) of the tested natural extract that inhibited visible bacterial growth. Corresponding inhibition zones from the disk diffusion assay (DDA) are reported in millimeters (mm).

EO A	S. aureus	E. faecalis	B. cereus	S. typhi	E. coli	L. monocytogenes
DDA (mm)	6.5±0.04	5.8±0.1*	8.3±0.09**	10.8±0.02**	8.5±0.09**	5.4±0.02*
MIC ($\mu\text{g}/\text{mL}$)	125±0.02	579±0.06*	250±0.04**	125±0.09*	144±0.03**	544±0.07*

EO B	S. aureus	E. faecalis	B. cereus	S. typhi	E. coli	L. monocytogenes
DDA (mm)	8.6±0.06	5.7±0.02*	9.5±0.05**	8.7±0.01**	10.2±0.08*	5.2±0.04*
MIC ($\mu\text{g}/\text{mL}$)	100±0.07	576±0.04*	256±0.09**	100±0.01**	125±0.06**	566±0.02*

DDA: Diffusion disk; MIC: Minimum Inhibitory Concentration; antimicrobial assays were carried out by broth microdilution method in Nutrient Broth. Replicates were from three independent experiments. A two-way ANOVA

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70

showed significant effects for bacterial strain and assay type ($p < 0.001$), with a significant interaction effect ($p < 0.01$). Post-hoc Tukey's test was used to determine pairwise significance. Asterisks denote statistical significance compared to the mean antimicrobial activity across all strains and assays: $p < 0.05$ (*); $p < 0.01$ (**); $p < 0.001$ (***) . The significant interaction implies that antimicrobial efficacy depends on the combination of bacterial species and assay type.

In agreement with our findings, previous studies have reported that fresh citrus essential oils exhibit antibacterial activity against *B. cereus*, *E. coli* and *S. aureus*²¹. In the present study, both EO-A and EO-B demonstrated measurable antimicrobial activity, with EO-B generally exhibiting stronger inhibitory effects, particularly against *E. coli* and *S. typhi*. The antimicrobial effects observed for the EOs investigated in this study may be ascribed to their relative abundance in aromatic and phenolic molecules. Although the mechanism underlying the antibacterial action of phenolic compounds is not yet fully elucidated, it has been hypothesised that these molecules can interact with the active sites of key bacterial enzymes, inducing irreversible alterations in membrane permeability and cell wall integrity, ultimately leading to bacterial death²². These considerations are consistent with our results, where the largest inhibition zones were recorded against the Gram-negative strains *S. typhi* and *E. coli*, ranging

671 between 8.5 and 10.8 mm. Consistently, MIC values as low as 100–125 µg/mL
672 were determined for these strains, confirming their higher susceptibility to both
673 EOs. This finding is particularly noteworthy, since Gram-negative bacteria are
674 generally considered less susceptible to EOs due to the protective outer
675 membrane, rich in lipopolysaccharides and proteins, which limits the penetration
676 of hydrophobic molecules²³. Nevertheless, literature data indicate that volatile
677 constituents of citrus EOs—such as limonene and γ-terpinene—can disrupt the
678 bacterial membrane, inhibit respiration and ion transport, and thereby increase
679 membrane permeability²⁴. This mechanism provides a plausible explanation for
680 the measurable inhibitory action observed in this study. Furthermore, in
681 agreement with our results, the antibacterial activity of *C. limon* EOs has also
682 been documented against *L. monocytogenes* and *E. faecalis*. reported inhibition
683 zones and MIC values indicating that *L. monocytogenes* was among the most
684 sensitive Gram-positive strains to *C. limon* EO, while activity was also observed
685 against *E. faecalis*. These findings corroborate the moderate, yet significant
686 inhibitory effects obtained in these assays and suggest that the observed
687 antibacterial activity may be attributed to the specific chemical profile of the
688 investigated samples.

689 *Clinical findings*

690 *Clinical findings*

991 Before evaluating the short-term effects on skin hydration and mechanical
992 properties, the cutaneous tolerability of both formulations was confirmed through
993 a 48-hour occlusive patch test. No adverse skin reactions or irritation were
994 observed, indicating a good tolerability profile for both emulsions. A pilot short-
995 term clinical evaluation of o/w emulsions containing EO-A or EO-B revealed a
996 similar efficacy profile on the assessed skin parameters.

997 As reported in Table 8, both formulations induced a pronounced and statistically
998 significant increase in skin hydration after 1 hour, with mean percentage
999 variations of +89.0 % for EO-A and +84.0 % for EO-B (vs T0, $p < 0.001$),
700 confirming a strong short-term moisturizing effect. This finding is further
701 supported by the very large effect sizes observed for both treatments compared
702 to placebo ($d = 3.11$ and 3.76 , respectively), indicating a clear separation between
703 treated and untreated conditions.

704 In addition, assessment of skin softness indicated an overall improvement for
705 both formulations, with small-to-moderate effect sizes observed for both
706 treatments compared to placebo (EO-A: $d = 0.557$; EO-B: $d = 0.668$), suggesting
707 enhanced skin softness and improved biomechanical pliability.

708 With regard to skin elasticity, assessed through the Cutometer[®] R2 parameter,
709 EO-A showed a modest positive effect ($d = 0.331$), whereas EO-B exhibited a
710 negligible effect compared to placebo ($d = 0.058$), despite the statistical

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

significance observed versus baseline (+3.0% vs T0, $p < 0.01$). The variability observed, particularly in the placebo group, together with partial overlap of confidence intervals, suggests a certain degree of inter-individual response variability. All results are shown in Figure 3 a–b–c.

Previous studies have demonstrated that the viscoelastic properties of the skin are influenced by its hydration level, as the water content of the stratum corneum represents a key determinant of its flexibility and mechanical properties ²⁵. Further studies are warranted to elucidate the long-term effects and underlying mechanisms associated with these results. Skin parameters are reported in Supplementary material as Table S1.

Table 8. Effect of 1.0 % EO-A and EO-B o/w emulsion on the investigated skin parameter after 1-hour application, average value \pm SD.

Parameter	EO-A o/w emulsion average value \pm SD	EO-B o/w emulsion average value \pm SD	Placebo emulsion average value \pm SD
Skin Hydration	T0: 34.41 \pm 7.57 T1h: 63.54 \pm 10.30	T0: 34.70 \pm 7.72 T1h: 61.94 \pm 8.46	T0: 32.00 \pm 9.72 T1h: 33.29 \pm 10.17
Skin Softness	T0: 2.54 \pm 0.09 T1h: 2.60 \pm 0.10	T0: 2.51 \pm 0.08 T1h: 2.55 \pm 0.08	T0: 2.19 \pm 0.26 T1h: 2.12 \pm 0.39
Skin Elasticity (R2)	T0: 0.597 \pm 0.0258 T1h: 0.585 \pm 0.0224	T0: 0.603 \pm 0.0183 T1h: 0.621 \pm 0.0179	T0: 0.587 \pm 0.137 T1h: 0.567 \pm 0.180




Figure 3 . *in vivo* instrumental assessment of EO-A and EO-B creams after 1h topical application. Data are expressed as mean percentage change \pm SEM; (* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, ns: not significant, t-Student test T_{1h} vs T₀)

Conclusions

The successful findings of bioactive compounds in a matrix originally intended for waste and, together with the promising experimental outcomes support their potential use as multifunctional and eco-sustainable bioactive ingredients designed for innovative cosmetic formulations, and aimed at delivering natural, effective solutions to promote skin health.

A key strength of this work lies in the adoption of supercritical CO₂ extraction, which proved to be a pivotal enabling technology. This approach provided a solvent-free, highly selective, and tuneable extraction method, allowing the efficient recovery of thermolabile and non-polar compounds without inducing chemical alterations. It enabled the valorisation of exhausted lemon peels—by-products of Limoncello production—yielding essential oils (EO-A and EO-B) with preserved chemical integrity and high functional value.

GC-MS plays a fundamental role in the comprehensive chemical characterisation of the extracts. The integration of supercritical CO₂ extraction with GC-MS

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

46 constitutes a robust and advanced analytical platform, enabling rapid and
47 sensitive profiling of complex mixtures with minimal sample preparation and
48 reduced environmental impact. This combined approach significantly
49 strengthens the reliability, reproducibility, and depth of chemical insight, which
50 are essential for the standardisation and future industrial exploitation of such
51 bioactive ingredients.

52 EO-A and EO-B contributed significantly to the potent antioxidant capacity,
53 demonstrated by consistent radical scavenging activity, as well as antimicrobial
54 properties against gram-positive and gram-negative bacterial strains. *In vitro*
55 assays conducted on HaCaT cell lines confirmed the biocompatibility and
56 favourable safety profile of both EOs, exhibiting minimal cytotoxicity, thereby
57 supporting their suitability for topical application. Furthermore, clinical
58 evaluations revealed significant enhancements in skin hydration, skin softness
59 and elasticity further underscoring their potential to promote overall skin
60 wellness.

61 Moreover, it was found active in reducing collagenase and elastase enzyme
62 activities, inhibiting melanogenesis, and fighting *Cutibacterium*
63 *acnes*, suggesting a possible use as a cosmetic additive also against skin aging,
64 hyperpigmentation ²⁶.

65 However, further investigations are required to elucidate the molecular
66 mechanisms underlying the biological effects of lemon EOs on skin physiology.
67 Both formulations significantly improved skin hydration, with very large effects
68 compared to placebo, while softer and more moderate improvements were
69 observed in skin mechanical properties. Overall, EO-A showed a more consistent
70 performance across parameters, whereas EO-B exhibited greater variability,
71 particularly in elasticity. In this perspective, future research should encompass
72 larger and long-term clinical studies to confirm the preliminary results and to

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

Open Access Article. Published on 22 April 2022. Downloaded on 4/22/2026 1:01:13 PM.
This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.



773 further evaluate their potential cosmetic applications. While the present study
774 focuses on lemon peel waste from “Limoncello production”, the proposed
775 approach may be extended to other agro-industrial residues characterized by
776 similar biochemical compositions, although further investigation is required to
777 assess its applicability under different process and matrix conditions for a large-
778 scale application. requiring dedicated techno-economic and supply chain
779 analyses.

81 **Statements and Declarations**

82 **Competing Interests:**

83 The authors declare that they have no known competing financial interests or
84 personal relationships that could have appeared to influence the work reported
85 in this paper.

32 **Author contribution**

34 R.D.L. formal analysis, conceptualization, writing original draft, supervision;
35
36 I.N. validation, formal analysis, investigation; R.R validation, formal analysis,
37 788 investigation; D.D.M data curation; C.I validation, supervision; M.G. F. formal
38
39 789 analysis; data curation; M.V. formal analysis, T.P. data curation, T.D.S. data
40
41 790 curation, S.L. visualization, conceptualization; L.G. conceptualization, writing
42
43
44 791 original draft, supervision.
45
46 792

48 793 All authors have read and agreed to the published version of the manuscript.

Analyst Accepted Manuscript

Data availability

The authors declare that the data supporting the findings of this study are available within the paper. Should any raw data files be needed in another format they are available from the corresponding author upon reasonable request.

Fundings

This research received no fundings.

REFERENCES

1. J. S. Baik, S. S. Kim, J. A. Lee, T. H. Oh, J. Y. Kim, N. H. Lee and C. G. Hyun, *J Microbiol Biotechnol*, 2008, **18**, 74-79.
2. T. Ahmad, F. Esposito and T. Cirillo, *Food Bioscience*, 2024, **62**, 105194.
3. A. Barbulova, G. Colucci and F. Apone, *Journal*, 2015, **2**, 82-92.
4. P. S. Pavithra, N. Sreevidya and R. S. Verma, *Journal of Ethnopharmacology*, 2009, **124**, 151-153.
5. S.-S. KIM, J. S. BAIK, T.-H. OH, W.-J. YOON, N. H. LEE and C.-G. HYUN, *Bioscience, Biotechnology, and Biochemistry*, 2008, **72**, 2507-2513.
6. G. Russo, G. Iaccarino, M. Piccolo, M. G. Ferraro, R. Vecchione, L. Grumetto, P. A. Netti and R. Santamaria, *Eur J Pharm Sci*, 2021, **162**, 105825.
7. R.-.-E.-C. P. R.-E.-L. (n.d.).
8. J. D. Johansen, K. Aalto-Korte, T. Agner, K. E. Andersen, A. Bircher, M. Bruze, A. Cannavó, A. Giménez-Arnau, M. Gonçalo, A. Goossens, S. M. John, C. Lidén, M. Lindberg, V. Mahler, M. Matura, T. Rustemeyer, J. Serup, R. Spiewak, J. P. Thyssen, M. Vigan, I. R. White, M. Wilkinson and W. Uter, *Contact Dermatitis*, 2015, **73**, 195-221.
9. C. Trojahn, G. Dobos, A. Lichterfeld, U. Blume-Peytavi and J. Kottner, *BioMed Research International*, 2015, **2015**, 318586.
10. D. Magalhães, A. A. Vilas-Boas, P. Teixeira and M. Pintado, *Foods*, 2023, **12**, 1095.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
11. H. Fraguera-Meissimilly, J. M. Bastías-Monte, C. Vergara, J. Ortiz-Viedma, R. Lemus-Mondaca, M. Flores, P. Toledo-Merma, S. Alcázar-Alay and M. Gallón-Bedoya, *Journal*, 2023, **28**, 4421.
 12. S. M. Pourmortazavi and S. S. Hajimirsadeghi, *Journal of Chromatography A*, 2007, **1163**, 2-24.
 13. M. A. Ferhat, B. Y. Meklati and F. Chemat, *Flavour and Fragrance Journal*, 2007, **22**, 494-504.
 14. D. Dittmar and M. L. A. Schuttelaar, *Contact Dermatitis*, 2019, **80**, 101-109.
 15. M. Zielińska-Błajet and J. Feder-Kubis, *Journal*, 2020, **21**, 7078.
 16. , !!! INVALID CITATION !!! 14.
 17. R. Vona, L. Pallotta, M. Cappelletti, C. Severi and P. Matarrese, *Antioxidants (Basel)*, 2021, **10**.
 18. S. Tang, D. Sheehan, D. J. Buckley, P. A. Morrissey and J. P. Kerry, *International Journal of Food Science and Technology*, 2001, **36**, 685-692.
 19. R. Budiarto, A. Khalisha, D. N. Sari, T. Ujilestari, T. Wahyono, A. F. M. Azmi, D. N. Adli, E. D. Lusiana, P. I. Sitaresmi and M. M. Sholikin, *Chemical and Biological Technologies in Agriculture*, 2024, **11**, 147.
 20. A. Witaicenis, L. N. Seito, A. da Silveira Chagas, L. D. de Almeida, Jr., A. C. Luchini, P. Rodrigues-Orsi, S. H. Cestari and L. C. Di Stasi, *Phytomedicine*, 2014, **21**, 240-246.
 21. S. Prabuseenivasan, M. Jayakumar and S. Ignacimuthu, *BMC Complementary and Alternative Medicine*, 2006, **6**, 39.
 22. L. Bouarab-Chibane, V. Forquet, P. Lantéri, Y. Clément, L. Léonard-Akkari, N. Oulahal, P. Degraeve and C. Bordes, *Frontiers in Microbiology*, 2019, **Volume 10 - 2019**.
 23. S. C. Chao, D. G. Young and C. J. Oberg, *Journal of Essential Oil Research*, 2000, **12**, 639-649.
 24. W. Tang, Z. Zhang, D. Nie, S. Liu, Y. Li, M. Liu, Y. Zhang, N. Ou and Y. Li, *LWT*, 2023, **186**, 115215.
 25. R. Di Lorenzo, M. Maisto, L. Ricci, V. Piccolo, A. Marzocchi, G. Greco, G. C. Tenore and S. Laneri, *International Journal of Molecular Sciences*, 2024, **25**, 1677.
 26. X.-f. Chen, Y.-y. Ding, H.-r. Guan, C.-j. Zhou, X. He, Y.-t. Shao, Y.-b. Wang, N. Wang, B. Li, G.-y. Lv and S.-h. Chen, *Natural Product Communications*, 2024, **19**, 1934578X241254229.

1
2
3
4 **Declaration**

5 **Data Availability Statement**

6
7 The datasets generated and/or analyzed during the current study are included within the article.
8
9
10

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Open Access Article. Published on 22 April 2026. Downloaded on 4/22/2026 11:11:37 PM.
This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.



Analyst Accepted Manuscript